Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors...
COGENT BIOSCIENCES ANNOUNCES POSITIVE PART 1B DATA FROM SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg...
New collaboration with Kyruus Health to advance care access and outcomes for patients at Nicklaus Children’s Health System BOSTON, MA – Feb. 15, 2024 – Kyruus Health, the leading care access platform, and Nicklaus Children’s Health System, a nationally recognized...
TigerConnect is a 2024 Best in KLAS Award Winner for Clinical Communications TigerConnect ranked as a leading provider in the ambulatory and post-acute care categories SANTA MONICA, Calif., February 7, 2024 — TigerConnect, healthcare’s most trusted clinical...
Bluesight Demonstrates Industry-Leading Performance in Drug Diversion Detection; New Data Highlights 6.6X Advantage Over Competitors Bluesight’s ControlCheck delivers hard outcomes by identifying a diverter every two days ALEXANDRIA, Va., Feb. 7, 2024 — Bluesight, the...
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease – ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) –...
Recent Comments